Release Date: 18/04/18 13:34 Summary: Response to ASX Aware Letter Price Sensitive: Yes Download Document 560.66KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%